Cite
HARVARD Citation
Sturm, S. et al. (2019). A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier. British journal of clinical pharmacology. 85 (1), pp. 181-193. [Online].